LES Spring Meeting

May. 19, 2010-May. 21, 2010
Park Plaza Hotel
Boston, MA
lesusacanada.org/sp10

Description:

Results of the Global BioPharmaceutical Royalty Rates & Deal Terms Survey

Ben Bonifant, Vice President and head of our Business Development practice, will present the analysis behind the results of the Global BioPharmaceutical Royalty Rates & Deal Terms Survey.

Abstract:

Do You Know What's Happening in Your Markets?  Global BioPharmaceutical Royalty Rates & Deal Terms from the 2009 Global Survey by LES USA/Canada and LESI

Many sources of information on biopharmaceutical royalty rates and deal terms rely on Freedom of Information (FOI) sources from public companies in the United States, which only represent "material" deals that are generally more than five years old, or rely on press releases or public announcements which are often positioned for maximum publicity or promotional impact(i.e. the hyperbole of "BIO Bucks").

The Life Sciences Sectors of LES USA/Canada and LESI have partnered to conduct a landmark GLOBAL survey of royalty rates and deal terms for deals conducted in the past two years (2008, 2009).

The results represent deals submitted by over 200 companies with approximately one-half the deals submitted by companies outside the USA/Canada.

This Landmark Global Survey is a first of its' kind for the biopharmaceutical industry. The Preliminary Results presented will be highlights of the Survey Report to be published July 2010.  The findings provide insights certain to raise questions or challenge conventional thinking, espcially for contemporary deals in the recent turbulent years.

James McCarthy, Senior Vice President, Corporate Development, EGEN, Inc.
Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance

View Entire Event Calendar

Don't Miss